Skip to main content

Articles

Page 2 of 15

  1. Morbidity and mortality related to opioid use disorder (OUD) in the U.S. is at an all-time high. Innovative approaches are needed to address gaps in retention in treatment with medications for opioid use disor...

    Authors: Jacqueline Hodges, Marika Waselewski, William Harrington, Taylor Franklin, Kelly Schorling, Jacqueline Huynh, Alexa Tabackman, Kori Otero, Karen Ingersoll, Nassima Ait-Daoud Tiouririne, Tabor Flickinger and Rebecca Dillingham
    Citation: Addiction Science & Clinical Practice 2022 17:16
  2. The prevalence of alcohol use disorder (AUD) among women in South Korea has been rising, causing public health problems. Yet women’s treatment needs are mostly unmet in South Korea due to the lack of women-foc...

    Authors: Insuk Lee, Mihyoung Lee and Scott Seung W. Choi
    Citation: Addiction Science & Clinical Practice 2022 17:14
  3. We have previously shown that service-wide support can increase the odds of alcohol screening in any 2-month period in a cluster randomized trial of service-wide support to Aboriginal and Torres Strait Islande...

    Authors: Monika Dzidowska, Jacques E. Raubenheimer, Timothy A. Dobbins, K. S. Kylie Lee, Noel Hayman, Julia Vnuk, Paul Haber and Katherine M. Conigrave
    Citation: Addiction Science & Clinical Practice 2022 17:13
  4. The cervical cancer burden is high among women living in Appalachia. Cigarette smoking, a cervical cancer risk factor, is also highly prevalent in this population. This project aims to increase smoking cessati...

    Authors: Joanne G. Patterson, Tia N. Borger, Jessica L. Burris, Mark Conaway, Robert Klesges, Amie Ashcraft, Lindsay Hauser, Connie Clark, Lauren Wright, Sarah Cooper, Merry C. Smith, Mark Dignan, Stephenie Kennedy-Rea, Electra D. Paskett, Roger Anderson and Amy K. Ferketich
    Citation: Addiction Science & Clinical Practice 2022 17:11

    The Correction to this article has been published in Addiction Science & Clinical Practice 2022 17:21

  5. Substance use disorders, depression and anxiety disproportionately affect people with HIV (PWH) and lead to increased morbidity and mortality. Routine screening can help address these problems but is underutil...

    Authors: Alexandra N. Lea, Andrea Altschuler, Amy S. Leibowitz, Tory Levine-Hall, Jennifer McNeely, Michael J. Silverberg and Derek D. Satre
    Citation: Addiction Science & Clinical Practice 2022 17:10
  6. Alcohol use disorder (AUD) is one of the leading etiologies for liver cirrhosis and liver transplantation. Few individuals with AUD receive guideline-based care in the form of screening, brief intervention, re...

    Authors: Emily Johnson, Sumantra Monty Ghosh, Vijay John Daniels, T. Cameron Wild, Puneeta Tandon and Ashley Hyde
    Citation: Addiction Science & Clinical Practice 2022 17:9
  7. Interventions are needed to improve the quality of South Africa’s substance use disorder (SUD) treatment system. This study aimed to identify factors associated with patient-reported suboptimal access, quality...

    Authors: Bronwyn Myers, J. Randy Koch, Kim Johnson and Nadine Harker
    Citation: Addiction Science & Clinical Practice 2022 17:8
  8. To address the US opioid epidemic, there is an urgent clinical need to provide persons with opioid use disorder (OUD) with effective medication treatments for OUD (MOUD). Formulations of sublingual buprenorphi...

    Authors: Ismene Petrakis, Sandra A. Springer, Cynthia Davis, Elizabeth Ralevski, Lucy Gu, Robert Lew, John Hermos, Melynn Nuite, Adam J. Gordon, Thomas R. Kosten, Edward V. Nunes, Robert Rosenheck, Andrew J. Saxon, Robert Swift, Alexa Goldberg, Robert Ringer…
    Citation: Addiction Science & Clinical Practice 2022 17:6
  9. Medications to treat opioid use disorder (OUD) including buprenorphine products are evidence-based and cost-effective tools for combating the opioid crisis. However, limited availability to buprenorphine is pe...

    Authors: Kevin P. Conway, Dalia Khoury, Rainer Hilscher, Arnie P. Aldridge, Stephanie J. Parker and Gary A. Zarkin
    Citation: Addiction Science & Clinical Practice 2022 17:5
  10. Extended-release buprenorphine (XRB) offers a novel approach to sustained monthly treatment for people who use opioids in criminal justice settings (CJS). This study explores the experiences of adults receivin...

    Authors: Anna Cheng, Ryan Badolato, Andrew Segoshi, Ryan McDonald, Mia Malone, Kumar Vasudevan, Beita Badiei, Allison Sugarman, Ross Macdonald, Jasdeep Mangat, Jonathan Giftos, Joshua D. Lee and Babak Tofighi
    Citation: Addiction Science & Clinical Practice 2022 17:4
  11. A quarter of pregnant women use alcohol, 6.5/1000 deliveries are affected by opioid use disorder (OUD), and the prevalence of cannabis use in pregnant women is increasing. However, marijuana co-exposure in pol...

    Authors: Kimberly Page, Cristina Murray-Krezan, Lawrence Leeman, Mary Carmody, Julia M. Stephen and Ludmila N. Bakhireva
    Citation: Addiction Science & Clinical Practice 2022 17:3
  12. Smoking cessation is the most effective means of slowing the decline of lung function associated with chronic obstructive pulmonary disease (COPD). While effective smoking cessation treatments are available, t...

    Authors: Elizabeth R. Stevens, Lei Lei, Charles M. Cleland, Mahathi Vojjala, Omar El-Shahawy, Kenneth I. Berger, Thomas R. Kirchner and Scott E. Sherman
    Citation: Addiction Science & Clinical Practice 2022 17:2
  13. Chronic obstructive pulmonary disease (COPD) causes 3 million deaths each year, yet 38% of COPD patients continue to smoke. Despite proof of effectiveness and universal guideline recommendations, smoking cessa...

    Authors: Samir Gupta, Puru Panchal, Mohsen Sadatsafavi, Parisa Ghanouni, Don Sin, Smita Pakhale, Teresa To, Zafar Zafari and Laura Nimmon
    Citation: Addiction Science & Clinical Practice 2022 17:1
  14. In the United States, methadone for opioid use disorder (OUD) is limited to highly regulated opioid treatment programs (OTPs), rendering it inaccessible to many patients. The “72-hour rule” allows non-OTP prov...

    Authors: Jordana Laks, Jessica Kehoe, Natalija M. Farrell, Miriam Komaromy, Jonathan Kolodziej, Alexander Y. Walley and Jessica L. Taylor
    Citation: Addiction Science & Clinical Practice 2021 16:73
  15. In the United States, methadone for opioid use disorder (OUD) is highly regulated. Federal agencies announced guidelines in March 2020 allowing for relaxation of take-home methadone dispensing at opioid treatm...

    Authors: Ximena A. Levander, Kim A. Hoffman, John W. McIlveen, Dennis McCarty, Javier Ponce Terashima and P. Todd Korthuis
    Citation: Addiction Science & Clinical Practice 2021 16:72
  16. Poppy seeds contain morphine and other opioid alkaloids and are commercially available in the United States. Users of poppy seed tea (PST) can consume several hundred morphine milligram equivalents per day, an...

    Authors: Scott Hagan, Carol E. Achtmeyer, Carly Hood, Eric J. Hawkins and Emily C. Williams
    Citation: Addiction Science & Clinical Practice 2021 16:71
  17. Patients with opioid use disorder (OUD) display an interindividual variability in their response to medications for opioid use disorder (MOUD). A genetic basis may explain the variability in this response. How...

    Authors: Caroul Chawar, Alannah Hillmer, Stephanie Sanger, Alessia D’Elia, Balpreet Panesar, Lucy Guan, Dave Xiaofei Xie, Nandini Bansal, Aamna Abdullah, Flavio Kapczinski, Guillaume Pare, Lehana Thabane and Zainab Samaan
    Citation: Addiction Science & Clinical Practice 2021 16:70
  18. The Problematic Online Gaming Questionnaire (POGQ) is an 18-item self-rated measure designed to assess the degree of problematic online gaming. This study translated the POGQ into Japanese (POGQ-J) and examine...

    Authors: Kazuya Inoue, Kengo Yokomitsu, Tomonari Irie, Makoto Matsuyama and Masanori Tanaka
    Citation: Addiction Science & Clinical Practice 2021 16:69
  19. The COVID-19 pandemic has exerted a significant toll on the lives of people who use opioids (PWUOs). At the same time, more flexible regulations around provision of opioid use disorder (OUD) services have led ...

    Authors: Noa Krawczyk, Adetayo Fawole, Jenny Yang and Babak Tofighi
    Citation: Addiction Science & Clinical Practice 2021 16:68
  20. The CHOICES study randomized participants with HIV and opioid use disorder (OUD) to HIV clinic-based extended-release naltrexone (XR-NTX), which requires complete cessation of opioid use, versus treatment-as-u...

    Authors: Kim A. Hoffman, Robin Baker, Laura C. Fanucchi, Paula J. Lum, Lynn E. Kunkel, Javier Ponce Terashima, Dennis McCarty, Petra Jacobs and P. Todd Korthuis
    Citation: Addiction Science & Clinical Practice 2021 16:67
  21. The emergency department (ED) offers an important opportunity to identify patients with opioid use disorder (OUD) and initiate treatment. However, post-ED follow-up is challenging, and novel approaches to enha...

    Authors: Kathryn Hawk, Caitlin Malicki, Jeremiah Kinsman, Gail D’Onofrio, Andrew Taylor and Arjun Venkatesh
    Citation: Addiction Science & Clinical Practice 2021 16:66
  22. Few studies have examined links between current alcohol dependence and specific harms among Indigenous Australians. We investigated these associations as well as help seeking for drinking, awareness of local t...

    Authors: Teagan J. Weatherall, James H. Conigrave, Katherine M. Conigrave, Jimmy Perry, Scott Wilson, Robin Room, Tanya Chikritzhs and K. S. Kylie Lee
    Citation: Addiction Science & Clinical Practice 2021 16:65
  23. Medications for opioid use disorder such as opioid agonist treatment (OAT, including methadone, buprenorphine) are the gold standard intervention for opioid use disorder (OUD). Persons with OUD have high rates...

    Authors: Travis M. Scott, Julia Arnsten, James Patrick Olsen, Franchesca Arias, Chinazo O. Cunningham and Monica Rivera Mindt
    Citation: Addiction Science & Clinical Practice 2021 16:64
  24. Alcohol is challenging to discuss, and patients may be reluctant to disclose drinking partly because of concern about being judged. This report presents an overview of the development of a medications review i...

    Authors: Jim McCambridge, Karl Atkin, Ranjita Dhital, Brent Foster, Brendan Gough, Mary Madden, Stephanie Morris, Ronan O’Carroll, Margaret Ogden, Anne Van Dongen, Sue White, Cate Whittlesea and Duncan Stewart
    Citation: Addiction Science & Clinical Practice 2021 16:63
  25. Opioid-related overdoses and harms have been declared a public health emergency in the United States, highlighting an urgent need to implement evidence-based treatments. Contingency management (CM) is one of t...

    Authors: Sara J. Becker, Cara M. Murphy, Bryan Hartzler, Carla J. Rash, Tim Janssen, Mat Roosa, Lynn M. Madden and Bryan R. Garner
    Citation: Addiction Science & Clinical Practice 2021 16:61
  26. Methamphetamine/amphetamine use has sharply increased among people with opioid use disorder (OUD). It is therefore important to understand whether and how use of these substances may impact receipt of, and out...

    Authors: Madeline C. Frost, Hannah Lampert, Judith I. Tsui, Matthew D. Iles-Shih and Emily C. Williams
    Citation: Addiction Science & Clinical Practice 2021 16:62
  27. Emergency Departments (EDs) are important arenas for the detection of unhealthy substance use. Screening, Brief Intervention, and Referral to Treatment (SBIRT) for unhealthy alcohol use has been used in some E...

    Authors: Ditte Maria Sivertsen, Ulrik Becker, Ove Andersen and Jeanette Wassar Kirk
    Citation: Addiction Science & Clinical Practice 2021 16:60
  28. Urine drug screening (UDS) is commonly used as part of treatment for opioid use disorder (OUD), including treatment with buprenorphine-naloxone for OUD in a primary care setting. Very little is known about th...

    Authors: Halle G. Sobel, Jill S. Warrington, Samuel Francis-Fath, Abigail M. Crocker and Claudia A. Berger
    Citation: Addiction Science & Clinical Practice 2021 16:59
  29. Stimulant use has increased across the US, with concomitant opioid and methamphetamine use doubling between 2011 and 2017. Shifting patterns of polysubstance use have led to rising psychostimulant-involved dea...

    Authors: Mimi Yen Li, George A. Alba, Julian Mitton and Benjamin Bearnot
    Citation: Addiction Science & Clinical Practice 2021 16:57
  30. Nonmedical use of prescription opioids (defined as taking opioid medications for hedonic effects or in a manner other than prescribed) and the use of heroin have emerged in recent years as major public health ...

    Authors: Elizabeth J. D’Amico, Daniel L. Dickerson, Anthony Rodriguez, Ryan A. Brown, David P. Kennedy, Alina I. Palimaru, Carrie Johnson, Rosanna Smart, David J. Klein, Jennifer Parker, Keisha McDonald, Michael J. Woodward and Ninna Gudgell
    Citation: Addiction Science & Clinical Practice 2021 16:56
  31. Improving access to medication treatment of opioid use disorder (MOUD) is a national priority, yet common modifiable barriers (e.g., limited provider knowledge, negative beliefs about MOUD) often challenge imp...

    Authors: Eric J. Hawkins, Anissa N. Danner, Carol A. Malte, Brittany E. Blanchard, Emily C. Williams, Hildi J. Hagedorn, Adam J. Gordon, Karen Drexler, Jennifer L. Burden, Jennifer Knoeppel, Aline Lott, George G. Sayre, Amanda M. Midboe and Andrew J. Saxon
    Citation: Addiction Science & Clinical Practice 2021 16:55
  32. Findings have been mixed as to whether brief intervention (BI) is appropriate and effective for individuals with more severe alcohol use problems. Motivation to change drinking has been supported as a mechanis...

    Authors: Lindsay R. Meredith, Erica N. Grodin, Mitchell P. Karno, Amanda K. Montoya, James MacKillop, Aaron C. Lim and Lara A. Ray
    Citation: Addiction Science & Clinical Practice 2021 16:54
  33. Opioid use is one of the most critical public health issues as highly potent opioids contribute to rising rates of accidental opioid-related toxicity deaths. This crisis has affected people from all age groups...

    Authors: Kirsten Marchand, Corinne Tallon, Christina Katan, Jill Fairbank, Oonagh Fogarty, Katrina Marie Pellatt, Roxanne Turuba, Steve Mathias and Skye Barbic
    Citation: Addiction Science & Clinical Practice 2021 16:53
  34. The advent of direct-acting antivirals (DAAs)—a form of hepatitis C (HCV) treatment associated with shorter treatment course and greater efficacy—offers an unprecedented opportunity to eliminate HCV, but only ...

    Authors: Judith I. Tsui, Michael P. Barry, Elizabeth J. Austin, Elsa W. Sweek, Elyse Tung, Ryan N. Hansen, Michael Ninburg, John D. Scott, Sara N. Glick and Emily C. Williams
    Citation: Addiction Science & Clinical Practice 2021 16:52
  35. The Veterans Health Administration (VHA) is invested in expanding access to medication treatment for opioid use disorder (MOUD) to save lives. Access varies across VHA facilities and, thus, requires implementa...

    Authors: Allison M. Gustavson, Marie E. Kenny, Jennifer P. Wisdom, Hope A. Salameh, Princess E. Ackland, Adam J. Gordon and Hildi J. Hagedorn
    Citation: Addiction Science & Clinical Practice 2021 16:51
  36. The COVID-19 pandemic has created a crisis in access to addiction treatment. Programs with residential components have been particularly impacted as they try to keep infection from spreading in facilities and ...

    Authors: Kimberly A. Johnson, Carolyn Keough, Holly Hills, Wouter Vermeer, Rebecca Lengnick-Hall, Moira McNulty, Mark McGovern and Hendricks Brown
    Citation: Addiction Science & Clinical Practice 2021 16:49
  37. Smoking is more prevalent and persistent among lower socio-economic status (SES) compared with higher-SES groups, and contributes greatly to SES-based health inequities. Few interventions exist that effectivel...

    Authors: Eline Meijer, Janneke S. Korst, Kristiene G. Oosting, Eline Heemskerk, Sander Hermsen, Marc C. Willemsen, Bas van den Putte, Niels H. Chavannes and Jamie Brown
    Citation: Addiction Science & Clinical Practice 2021 16:48
  38. Little is known about prevalence and treatment of OUD among youth engaged in primary care (PC). Medications are the recommended treatment of opioid use disorder (OUD) for adolescents and young adults (youth). ...

    Authors: Sarah M. Bagley, Laura Chavez, Jordan M. Braciszewski, Mary Akolsile, Denise M. Boudreau, Gwen Lapham, Cynthia I. Campbell, Gavin Bart, Bobbi Jo H. Yarborough, Jeffrey H. Samet, Andrew J. Saxon, Rebecca C. Rossom, Ingrid A. Binswanger, Mark T. Murphy, Joseph E. Glass and Katharine A. Bradley
    Citation: Addiction Science & Clinical Practice 2021 16:46
  39. Office-Based Opioid Treatment (OBOT) is a delivery model which seeks to make medications for opioid use disorder (MOUD), particularly buprenorphine, widely available in general medical clinics and offices. Des...

    Authors: Dominic Hodgkin, Constance Horgan and Gavin Bart
    Citation: Addiction Science & Clinical Practice 2021 16:45
  40. Support from family and other social network elements can be important in helping patients to cope with practical and emotional consequences of diseases. The aim of the study was to examine perception of famil...

    Authors: Bente Birkeland, Bente Weimand, Torleif Ruud, Darryl Maybery and John-Kåre Vederhus
    Citation: Addiction Science & Clinical Practice 2021 16:44
  41. Compared to smokers with favorable socio-economic position (SEP), those with low SEP are less likely to have a successful smoking cessation attempt. Tailored approaches are therefore needed, and general practi...

    Authors: Mégane Héron, Anne-Laurence Le Faou, Gladys Ibanez, Brigitte Métadieu, Maria Melchior and Fabienne El-Khoury Lesueur
    Citation: Addiction Science & Clinical Practice 2021 16:43
  42. Patients with opioid use disorder (OUD) often have complex health care needs. Methadone is one of the medications for opioid use disorder (MOUD) used in the management of OUDs. Highly restrictive methadone tre...

    Authors: Kerry Marshall, Geoffrey Maina and Jordan Sherstobitoff
    Citation: Addiction Science & Clinical Practice 2021 16:42
  43. There is no longer support for the idea that brief intervention programmes alone can contribute meaningfully to the improvement of population health relating to alcohol. As a result, calls for major innovation...

    Authors: Jim McCambridge
    Citation: Addiction Science & Clinical Practice 2021 16:41

    The Correction to this article has been published in Addiction Science & Clinical Practice 2021 16:58

  44. Opioid use disorder (OUD) disproportionately impacts rural and American Indian communities and has quadrupled among pregnant individuals nationwide in the past two decades. Yet, limited data are available abou...

    Authors: A. Taylor Kelley, Marcela C. Smid, Jacob D. Baylis, Elizabeth Charron, Amy E. Binns-Calvey, Shayla Archer, Saul J. Weiner, Lori Jo Begaye and Gerald Cochran
    Citation: Addiction Science & Clinical Practice 2021 16:40
  45. Most Americans with opioid use disorder (OUD) do not receive indicated medical care. A clinical decision support (CDS) tool for primary care providers (PCPs) could address this treatment gap. Our primary objec...

    Authors: Rebecca C. Rossom, JoAnn M. Sperl-Hillen, Patrick J. O’Connor, A. Lauren Crain, Laurel Nightingale, Anne Pylkas, Kristen V. Huntley and Gavin Bart
    Citation: Addiction Science & Clinical Practice 2021 16:37

Affiliated with

Annual Journal Metrics

Archival content

Addiction Science & Clinical Practice was formerly published by NIDA and previous issues of the journal can be viewed here.